FDA approval for Lupin’s Minzoya

19 February 2024
lupin-big

India-based generic drugmaker Lupin Limited (BSE: 500257) has received approval from the US Food and Drug Administration (FDA) for its Abbreviated New Drug Application for Minzoya (levonorgestrel and ethinyl estradiol tablets, USP and ferrous bisglycinate tablets), 0.1 mg/0.02 mg and 36.5 mg, to market a generic equivalent of Balcoltra of USA-based specialty drugmaker Avion Pharmaceuticals.

Minzoya Tablets are indicated for use by females of reproductive potential to prevent pregnancy, and the product will be manufactured at Lupin’s Pithampur facility in India.

Levonorgestrel and ethinyl estradiol tablets, USP and ferrous bisglycinate tablets( RLD Balcoltra) had estimated annual sales of $42 million in the USA, according to IQVIA (MAT December 2023).

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Generics